Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention
International Journal of Cancer · 01.04.2026 · 158 (7) · 1927-1940
DOI: 10.1002/ijc.70226 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 27.11.2025. Verfasst von Atieh Hajirahimkhan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Sterol Regulatory Element Binding Protein 1, Chalcones, Lipogenesis, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northwestern University Department of Surgery Seed funding, National Cancer Institute T32 postdoctoral fellowship, American Cancer Society.
Abstract (Originalsprache)
Anti‐estrogens have had a limited impact on breast cancer (BC) prevention. Novel agents with better tolerability, and efficacy beyond estrogen receptor (ER) positive BC are needed. We studied licochalcone A (LicA) for ER‐agnostic BC prevention. We demonstrated that LicA significantly reduced proliferation in seven human breast cell lines and suppressed ER+ and ER− xenograft tumors in mice. We confirmed these observations ex vivo in the contralateral unaffected breast (CUB) of women with unilateral sporadic BC, and BC cell lines using RNA sequencing, metabolism flux modeling, confirmatory NanoString nCounter metabolic pathway panel analysis in independent sets of specimens, proteomics, and western blots. We found that LicA targets sterol regulatory element binding protein 1 (SREBP1) with subsequent metabolic‐inflammatory changes, lowering spatiotemporally resolved cholesterol levels inside malignant cells to the levels in normal mammary cells. Mechanistically, in CUBs we observed that LicA downregulated PI3K‐AKT‐SREBP1‐dependent lipogenesis, NF‐kB‐dependent inflammation, and de novo nucleotide biosynthesis, stalling proliferation. Studies in cell lines showed suppression of PI3K and AKT phosphorylation, SREBP1 protein expression, and the SREBP1‐dependent enzymes such as ACAT2, ACLY, FASN, SCD, consistent with reduced NEDD8 required for SREBP1 stabilization. We found a significant reduction in NF‐kB expression, its nuclear translocation mediator karyopherin β 1, and prostaglandin E2 synthesis. We demonstrated a reduction in PRPS1‐catalyzed de novo nucleotide biosynthesis, and downregulation of proliferative markers MKI67, RRM2, and the survival marker BCL2. LicA reduces pro‐tumorigenic aberrations in lipid homeostasis and inflammation through SREBP1. It is a promising non‐endocrine candidate for BC prevention. Future studies in immunocompetent BC prevention models are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
- Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois, USA.
- Department of Preventive Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Chemistry, University of Illinois Chicago, Chicago, Illinois, USA.
ORCID-Profile: Atieh Hajirahimkhan, Elizabeth T Bartom, Carolina H Chung, Kyli Berkley, Seyyedmohsen Hosseinibarkooie, Shao Huan Samuel Weng, Raymond Moellering, Oukseub Lee, Ruohui Chen, Wonhwa Cho, Sriram Chandrasekaran, Susan E Clare, Seema A Khan
Förderung
- Northwestern University Department of Surgery Seed funding
- National Cancer Institute T32 postdoctoral fellowship
- American Cancer Society
- NIH HHS
- NIGMS NIH HHS
- Bramsen-Hamill Foundation
- Robert H Lurie Comprehensive Cancer Center Translational Bridge Fellowship
- NCI NIH HHS
Zitieren
APA
Hajirahimkhan, A., Bartom, E. T., Chung, C. H., Guo, X., Berkley, K., Hosseinibarkooie, S., Assadi, Z., Weng, S. H. S., Moellering, R., Lee, O., Chen, R., Cho, W., Chandrasekaran, S., Clare, S. E., & Khan, S. A. (2026). Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention. International Journal of Cancer, 158(7), 1927-1940. https://doi.org/10.1002/ijc.70226
Vancouver
Hajirahimkhan A, Bartom ET, Chung CH, Guo X, Berkley K, Hosseinibarkooie S, et al. Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention. International Journal of Cancer. 2026;158(7):1927-1940. doi:10.1002/ijc.70226
BibTeX
@article{Hajirahimkhan2026,
author = {Hajirahimkhan, Atieh and Bartom, Elizabeth T and Chung, Carolina H and Guo, Xingyu and Berkley, Kyli and Hosseinibarkooie, Seyyedmohsen and Assadi, Zahra and Weng, Shao Huan Samuel and Moellering, Raymond and Lee, Oukseub and Chen, Ruohui and Cho, Wonhwa and Chandrasekaran, Sriram and Clare, Susan E and Khan, Seema A},
title = {Reprogramming SREBP1 ‐dependent lipogenesis and inflammation in high‐risk breast with licochalcone A: A novel path to cancer prevention},
journal = {International Journal of Cancer},
year = {2026},
volume = {158},
number = {7},
pages = {1927--1940},
doi = {10.1002/ijc.70226}
}
EUVIMED